Order Entry
Puerto Rico
ContactUsLinkComponent
Expression Profiling of Clinically Relevant CYPs Assay Kit
Expression Profiling of Clinically Relevant CYPs Assay Kit
Catalog # 103881-810
CAS Number:  
undefined
Expression Profiling of Clinically Relevant CYPs Assay Kit
Catalog # 103881-810
Supplier Number:  UGE1003-48
CAS Number:  
Restricted Products: To process your orders without delay, please provide the required business documentation to purchase this product.

To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:

  • • State issued document with your organization's Federal Tax ID Number
  • • State issued document with your organization's Resale Tax ID Number
  • • City or County issued Business License
  • • State Department of Health Services License
  • • Any other ID issued by the State that includes the business name & address

* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. Avantor will not lift restrictions for residential shipping addresses.

Specifications

  • Description:
    Expression profiling of clinically relevant CYPs assay kit
  • Cat. No.:
    103881-810
  • Format:
    2× 48 assays in 96-well format

Specifications

About this item

Eliminate weeks of cell culture while achieving superior sensitivity with reproducible results from INDIGO’s Expression Profiling of Clinically Relevant CYPs Utilizing upcyte Hepatocytes, 2×48 format.

  • Kit includes optimized reagents for the culturing and treatment of upcyte® hepatocytes to assess drug-induced changes in CYP3A4, CYP1A1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2E1
  • Exceptional cell viability post-thaw
  • Consistent results lot to lot (product quality data available upon request)

This Expression Profiling of Clinically Relevant CYPs assay kit contains optimized reagents for the culturing and treatment of upcyte® hepatocytes to assess drug-induced changes in CYP3A4, CYP1A1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2E1.

The kit provides two aliquots of upcyte® hepatocytes, two cell culture-ready assay plates, optimized Cell Culture Medium for use in all steps of the assay procedure, and three reference compounds (rifampicin, β-naphthoflavone, and CDCA) that activate one or more of the primary xenobiotic-sensing receptors: PXR, CAR, AhR, and FXR. Upon activation, these nuclear receptors modulate the expression of the CYP genes. Also included are seven sets of validated qPCR primers for quantifying drug-induced changes in the expression of CYP3A4, CYP1A1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2E1, as well as primers for ACTB.

Please note: This kit does not include reagents or protocols for cell lysis, RNA isolation, cDNA preparation, or qPCR assays.

Ordering information: Kits are all-inclusive assay systems featuring live cells.
Delivery: Kits are shipped via overnight delivery on dry ice. Due to extreme temperature-sensitivity of the live cells, kits must be stored at −80 °C.